FDA Approved Products
| Application # | Type | Sponsor | Notes | Product # | Drug Name | Form | Strength | Active Ingredient | Approval Date | Marketing Status | Reference Standard |
|---|
| 761411 | BLA | INCYTE CORP | | 001 | NIKTIMVO | INJECTABLE;INTRAVENOUS | 50 MG/ML | axatilimab-csfr | 2024-08-14 | Prescription | No |
| 761334 | BLA | INCYTE CORP | | 001 | ZYNYZ | INJECTABLE;INTRAVENOUS | 500MG/20ML(25MG/ML) | RETIFANLIMAB-DLWR | 2023-03-22 | Prescription | No |
| 215309 | NDA | INCYTE CORP | | 001 | OPZELURA | CREAM;TOPICAL | EQ 1.5% BASE | RUXOLITINIB PHOSPHATE | 2021-09-21 | Prescription | Yes |
| 213736 | NDA | INCYTE CORP | | 001 | PEMAZYRE | TABLET;ORAL | 4.5MG | PEMIGATINIB | 2020-04-17 | Prescription | No |
| 002 | PEMAZYRE | TABLET;ORAL | 9MG | PEMIGATINIB | 2020-04-17 | Prescription | No |
| 003 | PEMAZYRE | TABLET;ORAL | 13.5MG | PEMIGATINIB | 2020-04-17 | Prescription | Yes |
| 202192 | NDA | INCYTE CORP | | 001 | JAKAFI | TABLET;ORAL | EQ 5MG BASE | RUXOLITINIB PHOSPHATE | 2011-11-16 | Prescription | No |
| 002 | JAKAFI | TABLET;ORAL | EQ 10MG BASE | RUXOLITINIB PHOSPHATE | 2011-11-16 | Prescription | No |
| 003 | JAKAFI | TABLET;ORAL | EQ 15MG BASE | RUXOLITINIB PHOSPHATE | 2011-11-16 | Prescription | No |
| 004 | JAKAFI | TABLET;ORAL | EQ 20MG BASE | RUXOLITINIB PHOSPHATE | 2011-11-16 | Prescription | No |
| 005 | JAKAFI | TABLET;ORAL | EQ 25MG BASE | RUXOLITINIB PHOSPHATE | 2011-11-16 | Prescription | Yes |